person · Reporting owner

GAYNOR RICHARD

Disclosed activity across 4 companies

Tapewire entity: 31955
SEC CIK: 0001741284

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	May 20, 2026	May 22, 2026
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802	Director	June 16, 2022	June 16, 2022
Zai Lab LtdZLAB · Entity 4271	Director	July 01, 2026	July 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 20, 2026 · Filed May 22, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20	Direct	11,538	Reported balance After 2026-05-20 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	5,409	Reported balance After 2026-05-20 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F3: Each restricted stock unit represents a contingent right to receive one ordinary share. F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above.

Filing footnotes · ownership attribution and instrument terms

F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above.

F3: Each restricted stock unit represents a contingent right to receive one ordinary share.

INFINITY PHARMACEUTICALS, INC.

Report date June 16, 2022 · Filed June 16, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2032-06-16	Direct	45,000	Reported balance After 2022-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-16 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Zai Lab Ltd

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
American Depositary SharesSEC Table I · non-derivative	Direct	80,737	Reported balance After 2026-07-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-07-01 · Purchase · Acquired 1,736 · Balance 80,737 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Neon Therapeutics, Inc.

Report date May 06, 2020 · Filed May 06, 2020

Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-05-06 transaction · row 1 1 source row Row 1 · 2020-05-06 · Disposition to issuer · Disposed 210,410 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20	Direct	Reported balance After 2020-05-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-05-06 · Disposition to issuer · Disposed 58,005 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13	Direct	Reported balance After 2020-05-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-06 · Disposition to issuer · Disposed 105,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65	Direct	Reported balance After 2020-05-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-05-06 · Disposition to issuer · Disposed 155,373 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person.

F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2021 Filed Jun 11, 2021 16:15 UTC	INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0001140361-21-020645 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document
May 20, 2021 Filed May 21, 2021 20:35 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	6,104	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-017788 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This restricted stock unit award vested in full on 5/20/2021. F1 · derivative.expiration_date: This restricted stock unit award vested in full on 5/20/2021. Read SEC document
May 20, 2021 Filed May 21, 2021 20:35 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,404	$21.92	$30,775.68	Disclosure SEC source: 0001127602-21-017788 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Read SEC document
May 20, 2021 Filed May 21, 2021 20:35 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,104	$0.00	$0.00	Disclosure SEC source: 0001127602-21-017788 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 02, 2020 Filed Dec 4, 2020 21:33 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,578	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-030576 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,578 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. Read SEC document
December 02, 2020 Filed Dec 4, 2020 21:33 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,509	$0.00 Strike: $18.82	$0.00	Disclosure SEC source: 0001127602-20-030576 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,509 Underlying: Ordinary Shares · 11,509 shares Expires 2030-12-02 F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021. Read SEC document
May 20, 2020 Filed May 22, 2020 20:21 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	6,104	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-017769 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. Read SEC document
May 20, 2020 Filed May 22, 2020 20:21 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	12,823	$0.00 Strike: $16.85	$0.00	Disclosure SEC source: 0001127602-20-017769 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,823 Underlying: Ordinary Shares · 12,823 shares Expires 2030-05-20 F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021. Read SEC document
May 06, 2020 Filed May 6, 2020 21:06 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Disposition to issuerStock Option (Right to Buy) · Derivative	155,373	Not disclosed Strike: $2.65	Not disclosed	Disclosure SEC source: 0001694187-20-000065 · wf-form4_158881359090519.xml · derivative · entry 4 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,373 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. Read SEC document
May 06, 2020 Filed May 6, 2020 21:06 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Disposition to issuerStock Option (Right to Buy) · Derivative	105,000	Not disclosed Strike: $6.13	Not disclosed	Disclosure SEC source: 0001694187-20-000065 · wf-form4_158881359090519.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document
May 06, 2020 Filed May 6, 2020 21:06 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Disposition to issuerStock Option (Right to Buy) · Derivative	58,005	Not disclosed Strike: $10.20	Not disclosed	Disclosure SEC source: 0001694187-20-000065 · wf-form4_158881359090519.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,005 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document
May 06, 2020 Filed May 6, 2020 21:06 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Disposition to issuerCommon Stock	210,410	Not disclosed	Not disclosed	Disclosure SEC source: 0001694187-20-000065 · wf-form4_158881359090519.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person. Read SEC document
March 16, 2020 Filed Mar 17, 2020 16:34 UTC	INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $0.69	$0.00	Disclosure SEC source: 0000899243-20-008613 · doc4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-16 F1 · derivative.exercise_price: Represents the closing sale price per share of the Issuer's common stock as reported on the Nasdaq Global Select Market on the date of grant. F2 · derivative.exercise_date: The option vests as to 1/8th of the shares on March 31, 2020 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the Issuer. Read SEC document
February 29, 2020 Filed Mar 2, 2020 18:39 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Tax withholdingCommon Stock	5,625	$1.50	$8,437.50	Disclosure SEC source: 0001694187-20-000029 · wf-form4_158319234594040.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,410 F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on February 27, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 29, 2020. Read SEC document
February 25, 2020 Filed Feb 27, 2020 18:21 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	Tax withholdingCommon Stock	5,465	$1.51	$8,252.15	Disclosure SEC source: 0001694187-20-000012 · wf-form4_158284564352844.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,035 F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on November 25, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 25, 2020. Read SEC document
January 12, 2020 Filed Jan 13, 2020 17:01 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	GrantCommon Stock	65,000	$0.00	$0.00	Disclosure SEC source: 0001694187-20-000006 · wf-form4_157895284328015.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,500 F1 · shares: Dr. Gaynor was awarded 65,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on January 31, 2021 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
December 04, 2019 Filed Dec 9, 2019 21:11 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	61,800	$0.00 Strike: $21.23	$0.00	Disclosure SEC source: 0001127602-19-034549 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,800 Underlying: Ordinary Shares · 61,800 shares Expires 2029-12-04 F1 · date: Late filing due to administrative error. F3 · derivative.exercise_date: This option vests in 3 equal annual installments commencing on 12/4/2020. Read SEC document
December 04, 2019 Filed Dec 9, 2019 21:11 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,200	$0.00 Strike: $21.23	$0.00	Disclosure SEC source: 0001127602-19-034549 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Ordinary Shares · 11,200 shares Expires 2029-12-04 F1 · date: Late filing due to administrative error. F2 · derivative.exercise_date: This option becomes exercisable in full on 12/4/2020. Read SEC document
November 27, 2019 Filed Nov 27, 2019 17:01 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	SaleCommon Stock	22,322	$1.24	$27,643.56	Disclosure SEC source: 0001694187-19-000080 · wf-form4_157489210160884.xml · nonDerivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,500 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 26, 2019 Filed Nov 27, 2019 17:01 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	SaleCommon Stock	23,000	$1.31	$30,231.20	Disclosure SEC source: 0001694187-19-000080 · wf-form4_157489210160884.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,822 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 25, 2019 Filed Nov 25, 2019 17:25 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	GrantCommon Stock	75,000	$0.00	$0.00	Disclosure SEC source: 0001694187-19-000077 · wf-form4_157472068909037.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,822 F1 · shares: Dr. Gaynor was awarded 75,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest quarterly over one year, subject to the Reporting Person's continued service, with the first tranche vesting on February 25, 2020. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
November 25, 2019 Filed Nov 27, 2019 17:01 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	SaleCommon Stock	20,000	$1.37	$27,498.00	Disclosure SEC source: 0001694187-19-000080 · wf-form4_157489210160884.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,822 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.36 to $1.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 27, 2019 Filed Mar 1, 2019 18:19 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	GrantCommon Stock · Derivative	105,000	$0.00 Strike: $6.13	$0.00	Disclosure SEC source: 0001694187-19-000013 · wf-form4_155148234493134.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Stock Option (Right to Buy) · 105,000 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019. Read SEC document
February 27, 2019 Filed Mar 1, 2019 18:19 UTC	Neon Therapeutics, Inc. NTGN · Entity 149433	GrantCommon Stock	57,500	$0.00	$0.00	Disclosure SEC source: 0001694187-19-000013 · wf-form4_155148234493134.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,822 F1 · shares: Dr. Gaynor was awarded 57,500 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.